CO2018000768A2 - Administración intravenosa de citrulina durante la cirugía - Google Patents

Administración intravenosa de citrulina durante la cirugía

Info

Publication number
CO2018000768A2
CO2018000768A2 CONC2018/0000768A CO2018000768A CO2018000768A2 CO 2018000768 A2 CO2018000768 A2 CO 2018000768A2 CO 2018000768 A CO2018000768 A CO 2018000768A CO 2018000768 A2 CO2018000768 A2 CO 2018000768A2
Authority
CO
Colombia
Prior art keywords
intravenous administration
during surgery
citrulline
composition
citrulline during
Prior art date
Application number
CONC2018/0000768A
Other languages
English (en)
Inventor
Marshall Summar
Frederick Barr
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57601710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018000768(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of CO2018000768A2 publication Critical patent/CO2018000768A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3666—Cardiac or cardiopulmonary bypass, e.g. heart-lung machines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención provee una composición médica, la cual comprende dos componentes: (a) un fluido de reemplazo de hemoconcentración y (b) citrulina; y métodos para preparar esta composición combinando los dos componentes. La composición resultante se puede usar en cirugía cardíaca para mejorar los resultados quirúrgicos
CONC2018/0000768A 2015-06-29 2018-01-25 Administración intravenosa de citrulina durante la cirugía CO2018000768A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186085P 2015-06-29 2015-06-29
PCT/US2016/040138 WO2017004233A1 (en) 2015-06-29 2016-06-29 Intravenous administration of citrulline during surgery

Publications (1)

Publication Number Publication Date
CO2018000768A2 true CO2018000768A2 (es) 2018-07-10

Family

ID=57601710

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0000768A CO2018000768A2 (es) 2015-06-29 2018-01-25 Administración intravenosa de citrulina durante la cirugía

Country Status (13)

Country Link
US (1) US10525026B2 (es)
EP (1) EP3313390A4 (es)
JP (1) JP6876632B2 (es)
KR (1) KR102320547B1 (es)
AU (1) AU2016286115B9 (es)
BR (1) BR112017025768A2 (es)
CA (1) CA2990279C (es)
CO (1) CO2018000768A2 (es)
HK (1) HK1254855A1 (es)
IL (1) IL256608A (es)
MX (1) MX2017015664A (es)
RU (1) RU2733738C2 (es)
WO (1) WO2017004233A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10144706B2 (en) * 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10265286B2 (en) 2016-12-28 2019-04-23 Vanderbilt University Sequelae of cardiopulmonary bypass-induced pulmonary injury
AR111082A1 (es) * 2017-02-27 2019-05-29 Univ Vanderbilt Citrulina para el tratamiento de la crisis de células falciformes
US20230404956A1 (en) * 2022-06-21 2023-12-21 Asklepion Pharmaceuticals Llc Therapeutic window for citrulline therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US9486429B2 (en) 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
BRPI0710044A2 (pt) * 2006-04-04 2011-08-02 Nestec Sa tratamentos usando citrulina
CN101083589B (zh) 2007-07-13 2010-08-11 华为技术有限公司 无源光网络中的终端检测认证方法、装置及操作管理系统
CN201069480Y (zh) 2007-07-16 2008-06-04 何凎 透雾摄像机镜头
SG196863A1 (en) 2008-01-31 2014-02-13 Univ Vanderbilt Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage
WO2009099998A2 (en) 2008-01-31 2009-08-13 Vanderbilt University Therapeutic treatment for lung conditions

Also Published As

Publication number Publication date
WO2017004233A1 (en) 2017-01-05
AU2016286115A1 (en) 2018-02-15
KR102320547B1 (ko) 2021-11-01
RU2018103072A (ru) 2019-07-30
HK1254855A1 (zh) 2019-07-26
IL256608A (en) 2018-02-28
MX2017015664A (es) 2018-04-18
US10525026B2 (en) 2020-01-07
AU2016286115B9 (en) 2021-02-04
RU2018103072A3 (es) 2019-12-25
RU2733738C2 (ru) 2020-10-06
CA2990279A1 (en) 2017-01-05
JP2018519301A (ja) 2018-07-19
CA2990279C (en) 2022-07-05
BR112017025768A2 (pt) 2018-08-14
JP6876632B2 (ja) 2021-05-26
US20160374972A1 (en) 2016-12-29
EP3313390A4 (en) 2019-02-20
KR20180021803A (ko) 2018-03-05
EP3313390A1 (en) 2018-05-02
AU2016286115B2 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
CL2019001433A1 (es) Moduladores de la proteína core de la hepatitis b. (divisional solicitud 201800684)
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
DOP2017000271A (es) Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t
DOP2017000272A (es) Métodos de diagnóstico para tratamiento con linfocitos t
CO2018000768A2 (es) Administración intravenosa de citrulina durante la cirugía
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
BR112017005790A2 (pt) dispositivos de reparo vascular e métodos de uso
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CO2019001236A2 (es) Compuestos y métodos para la modulación de smn2
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
TW201613578A (en) Pharmaceutical combinations
UY35988A (es) Proceso para la producción de una solución inyectable de noradrenalina de baja concentración
DOP2017000014A (es) Métodos para mejorar el rendimiento miocárdico en pacientes con cirugía de fontan que utilizan composiciones de udenafilo
CO2018002534A2 (es) Métodos de sedación y formulación parenteral para uso durante el tratamiento de cuidados críticos
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
EA201792256A1 (ru) Соли и пролекарства 1-метил-d-триптофана
PE20161145A1 (es) Metodos y herramientas relacionados con la administracion de medio de contraste
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino